Skip to main content
SpringerLink
Log in

Regulatory watch

Characterizing the US FDA's approach to promoting transformative innovation

  • Biobusiness Briefs
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Characteristics of novel therapeutics approved by the FDA between 2005 and 2012, stratified by degree of innovation.

Author information

Authors and Affiliations

  1. Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Connecticut, USA

    Nicholas S. Downing, Harlan M. Krumholz & Joseph S. Ross

  2. Division of Health Care Policy and Research, Mayo Clinic, Rochester, Minnesota

    Nilay D. Shah

  3. Yale University School of Medicine, P.O. Box 208093, New Haven, 06520, Connecticut, USA

    Harlan M. Krumholz & Joseph S. Ross

Authors
  1. Nicholas S. Downing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harlan M. Krumholz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph S. Ross
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nilay D. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph S. Ross.

Ethics declarations

Competing interests

H. Krumholz and J. Ross are funded by research agreements through Yale University from Medtronic and Johnson & Johnson (Janssen) to develop methods of clinical trial data sharing, by the US Centers for Medicare & Medicaid Services to develop and maintain performance measures, and by the US Food and Drug Administration to develop methods for post-market surveillance of medical devices. H. Krumholz chairs a cardiac scientific advisory board for UnitedHealth. The other authors do not have competing interests to report.

Additional information

This research was not supported by any external grants or funds.

Related links

PowerPoint slides

Supplementary information

Supplementary information S1 (box)

Data and analysis (PDF 449 kb)

Supplementary information S2 (figure)

Novel therapeutics approved by the FDA between 2005 and 2012 and their degree of innovation, stratified by drug type and therapeutic area. (PDF 113 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Downing, N., Krumholz, H., Ross, J. et al. Characterizing the US FDA's approach to promoting transformative innovation. Nat Rev Drug Discov 14, 740–741 (2015). https://doi.org/10.1038/nrd4734

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4734

  • Springer Nature Limited

This article is cited by

Search

Navigation